Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(21)00494-0 ◽

2021 ◽

Author(s):

Courtney D DiNardo ◽

Andre C Schuh ◽

Eytan M Stein ◽

Pau Montesinos ◽

Andrew H Wei ◽

...

Keyword(s):

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Phase 2 ◽

Newly Diagnosed ◽

Phase 2 Trial ◽

Phase 1B ◽

Download Full-text

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

The Lancet Haematology ◽

10.1016/s2352-3026(20)30210-6 ◽

2020 ◽

Vol 7 (10) ◽

pp. e724-e736 ◽

Author(s):

Courtney D DiNardo ◽

Abhishek Maiti ◽

Caitlin R Rausch ◽

Naveen Pemmaraju ◽

Kiran Naqvi ◽

...

Keyword(s):

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Intensive Chemotherapy ◽

Phase 2 ◽

Newly Diagnosed ◽

Single Centre ◽

Phase 2 Trial ◽

Download Full-text

Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial

The Lancet Haematology ◽

10.1016/s2352-3026(18)30182-0 ◽

2019 ◽

Vol 6 (1) ◽

pp. e29-e37 ◽

Author(s):

Nicholas J Short ◽

Hagop M Kantarjian ◽

Sanam Loghavi ◽

Xuelin Huang ◽

Wei Qiao ◽

...

Keyword(s):

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Older Patients ◽

Phase 2 ◽

Newly Diagnosed ◽

Phase 2 Trial ◽

Download Full-text

Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial

The Lancet Haematology ◽

10.1016/s2352-3026(21)00192-7 ◽

2021 ◽

Vol 8 (8) ◽

pp. e552-e561 ◽

Author(s):

Tapan M Kadia ◽

Patrick K Reville ◽

Gautam Borthakur ◽

Musa Yilmaz ◽

Steven Kornblau ◽

...

Keyword(s):

High Risk ◽

Acute Myeloid Leukaemia ◽

Myelodysplastic Syndrome ◽

Myeloid Leukaemia ◽

Intensive Chemotherapy ◽

Phase 2 ◽

Newly Diagnosed ◽

Single Centre ◽

Phase 2 Trial ◽

Download Full-text

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)00362-9 ◽

2015 ◽

Vol 16 (16) ◽

pp. 1691-1699 ◽

Author(s):

Christoph Röllig ◽

Hubert Serve ◽

Andreas Hüttmann ◽

Richard Noppeney ◽

Carsten Müller-Tidow ◽

...

Keyword(s):

Randomised Controlled Trial ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Standard Therapy ◽

Controlled Trial ◽

Phase 2 ◽

Newly Diagnosed ◽

Multicentre Phase ◽

Randomised Controlled ◽

Download Full-text

Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study

The Lancet Haematology ◽

10.1016/s2352-3026(19)30114-0 ◽

2019 ◽

Vol 6 (9) ◽

pp. e480-e488 ◽

Author(s):

Farhad Ravandi ◽

Rita Assi ◽

Naval Daver ◽

Christopher B Benton ◽

Tapan Kadia ◽

...

Keyword(s):

High Risk ◽

Acute Myeloid Leukaemia ◽

Myelodysplastic Syndrome ◽

Myeloid Leukaemia ◽

Phase 2 ◽

Newly Diagnosed ◽

Phase 2 Study ◽

Download Full-text

Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial

The Lancet Haematology ◽

10.1016/s2352-3026(17)30228-4 ◽

2018 ◽

Vol 5 (1) ◽

pp. e34-e43 ◽

Author(s):

Moshe Mittelman ◽

Uwe Platzbecker ◽

Boris Afanasyev ◽

Sebastian Grosicki ◽

Raymond S M Wong ◽

...

Keyword(s):

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Myelodysplastic Syndromes ◽

Severe Thrombocytopenia ◽

Phase 2 ◽

Phase 2 Trial ◽

Download Full-text

Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial

The Lancet Haematology ◽

10.1016/s2352-3026(20)30209-x ◽

2020 ◽

Vol 7 (8) ◽

pp. e566-e574 ◽

Author(s):

Justin Taylor ◽

Xiaoli Mi ◽

Alexander V Penson ◽

Stella V Paffenholz ◽

Kelsey Alvarez ◽

...

Keyword(s):

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Myelodysplastic Syndromes ◽

Hypomethylating Agents ◽

Phase 2 ◽

Single Centre ◽

Phase 2 Trial ◽

Download Full-text

Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial

The Lancet Haematology ◽

10.1016/s2352-3026(19)30203-0 ◽

2020 ◽

Vol 7 (2) ◽

pp. e122-e133 ◽

Author(s):

Andrew M Brunner ◽

Traci M Blonquist ◽

Daniel J DeAngelo ◽

Malgorzata McMasters ◽

Geoffrey Fell ◽

...

Keyword(s):

High Risk ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Induction Chemotherapy ◽

Phase 2 ◽

Phase 2 Trial ◽

Download Full-text

Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(18)30580-1 ◽

2018 ◽

Vol 19 (12) ◽

pp. 1668-1679 ◽

Author(s):

Uwe Platzbecker ◽

Jan Moritz Middeke ◽

Katja Sockel ◽

Regina Herbst ◽

Dominik Wolf ◽

...

Keyword(s):

Acute Myeloid Leukaemia ◽

Myelodysplastic Syndrome ◽

Myeloid Leukaemia ◽

Residual Disease ◽

Phase 2 ◽

Multicentre Phase ◽

Phase 2 Trial ◽

Measurable Residual Disease ◽

Download Full-text

A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia

British Journal of Haematology ◽

10.1111/bjh.14407 ◽

2016 ◽

Vol 176 (2) ◽

pp. 241-247 ◽

Author(s):

Amer M. Zeidan ◽

B. Douglas Smith ◽

Hetty E. Carraway ◽

Ivana Gojo ◽

Amy DeZern ◽

...

Keyword(s):

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Myelodysplastic Syndromes ◽

High Dose ◽

Phase 2 ◽

Phase 2 Trial ◽

Download Full-text